In contrast to complete inhibition of the NLRP3 inflammasome or its products, precise, selective inhibition of dyslipidemia-driven inflammasome activation in atherosclerosis may be less immunosuppressive, and, thus, clinically more acceptable as a therapeutic strategy to reduce CVD risk. The gene discussed is NLRP3; the disease is metabolic syndrome.